Trials / Completed
CompletedNCT00436293
Taxotere + Cisplatin in Nasopharyngeal Carcinoma
A Randomized Phase II Study of Concurrent Cisplatin-radiotherapy With or Without Neoadjuvant Chemotherapy Using Taxotere and Cisplatin in Advanced Nasopharyngeal Carcinoma (NPC)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Primary objective: To assess and compare the toxicities of patients with advanced NPC treated with concurrent cisplatin-radiotherapy with or without neoadjuvant Taxotere (docetaxel) and cisplatin. Secondary objective: To assess tumor control and survival
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel | 75 mg/m² |
| DRUG | Cisplatin | 75 mg/m² |
Timeline
- Start date
- 2002-12-01
- Primary completion
- 2010-03-01
- Completion
- 2010-03-01
- First posted
- 2007-02-19
- Last updated
- 2010-11-17
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT00436293. Inclusion in this directory is not an endorsement.